

Kenji Sukeno President and Chief Operating Officer July 27, 2018

Notice of Dissolution of a Subsidiary Company

FUJIFILM Corporation, a subsidiary of FUJIFILM Holdings Corporation today announced that it was decided to dissolve FUJIFILM Pharma Co., Ltd. (FUJIFILM Pharma), one of its consolidated subsidiaries as of March 31, 2019.

FUJIFILM Pharma has conducted business centering on generic drugs since the opening of business in 2010. Now that the circumstances surrounding the pharmaceutical industry are changing rapidly, it has been deemed difficult to secure stable profitability for the coming years based on the current business activities.

Now the Fujifilm Group (the Group) is pursuing a growth strategy related to healthcare business field. In the pharmaceutical business, FUJIFILM Toyama Chemical Co., Ltd. will be founded on October 1, 2018 with two group companies -TOYAMA CHEMICAL Co., Ltd. and FUJIFILM RI Pharma Co., Ltd.- merged. Positioning the newly founded company as a core entity, the Group aims to further expand this business by promoting development of new diagnostic and therapeutic drugs in the fields of "oncology", "central nervous system diseases", and "infectious diseases", all of which have considerable unmet medical needs, as well as development of drug delivery system (DDS) technologies that deliver the required amount of a drug to the specific area of the body on the necessary schedule. The Group also expands the offering of comprehensive solutions from "diagnosis" to "treatment" by utilizing in vitro diagnostic (IVD) devices and reagents, as well.

[Overview of FUJIFILM Pharma]

Company Name	FUJIFILM Pharma Co., Ltd.
Location	26-30, Nishiazabu 2-Chome, Minato-Ku, Tokyo, Japan
Representative	Susumu Tanahashi
Capital	50 million yen
Main Business Activities	Sales of generic drugs and long-term listed drugs
Establishment Date	November 2, 2009